cemsidomide
CFT7455 Small Molecule Target: IKZF1, IKZF3, IKZF1/3, cereblon
C4 Therapeutics
Most recent annual filing: 2026-02-15
- internal discovery pipeline IND candidateEnd of 2026internal discovery pipeline IND candidate, End of 2026, routine
- partnered pipeline partnershipBy year-end 2026partnered pipeline partnership, By year-end 2026, routine
- cemsidomide MOMENTUM trial enrollment done1Q 2027cemsidomide MOMENTUM trial enrollment done, 1Q 2027, routine
- MOMENTUM enrollment done1Q 2027MOMENTUM enrollment done, 1Q 2027, routine
- cemsidomide + elranatamab Ph1 readoutMid-2027cemsidomide + elranatamab Ph1 readout, Mid-2027, major
- cemsidomide MOMENTUM trial Ph2 interim2H 2027cemsidomide MOMENTUM trial Ph2 interim, 2H 2027, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (2 active programs)
CFT8919
Small Molecule Target: EGFR L858R
Technology platforms
TORPEDO
Proprietary targeted protein degradation platform — collection of computational and experimental tools for designing, analyzing, and predicting degrader performance; supports MonoDAC (molecular glue type) and BiDAC (heterobivalent) degraders with properties such as oral bioavailability, CNS penetration, enhanced potency, and selectivity; focus on oncology, inflammation, neuroinflammation, and neurodegeneration
Targets: IKZF1/3, EGFR L858R, IL-23/IL-17, Type 1 IFN, MAPK, PI3K/AKT, NF-kB
BIDAC · Roche
Bivalent degrader antibody conjugate platform technology used in collaboration with Roche for discovering and developing DACs against oncology targets.
MonoDAC
Molecular glue degrader modality producing orally bioavailable targeted protein degraders; disease focus: oncology including multiple myeloma
DAC · Roche
Degrader Antibody Conjugates (DACs) platform; C4T collaboration with Roche focused on discovering and developing DACs for two oncology programs
Biotech Distilled coverage (6)
- 2026-09-25 UPDATE: C4 Therapeutics (CCCC) - The Canary Survived Cohort One 🔒 Paid
- 2026-08-12 UPDATE: C4 Therapeutics (CCCC) - They Sold Stock They Said They Didn’t Need 🔒 Paid
- 2026-06-12 UPDATE: C4 Therapeutics (CCCC) - The EHA Print Holds, and the Depth Story Gets Real
- 2026-05-12 UPDATE: C4 Therapeutics (CCCC) - The CFT8919 Bonfire and the All-In Bet on Cemsidomide 🔒 Paid
- 2026-04-11 UPDATE: C4 Therapeutics (CCCC) - Roche Validates the DAC Modality and Pads the Balance Sheet 🔒 Paid
- 2026-04-01 C4 Therapeutics (CCCC) - Scientific Deep Dive for Cemsidomide and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.